Skip to main content
. Author manuscript; available in PMC: 2014 Nov 4.
Published in final edited form as: Vaccine. 2013 Sep 19;31(46):10.1016/j.vaccine.2013.09.003. doi: 10.1016/j.vaccine.2013.09.003

Fig. 6.

Fig. 6

HIV neutralization assay for sera or fecal extracts from mice orally immunized with BPV-gp41 CVLPs. (A, B and C) 200pg of HIV-1 viruses (clade B: HIV-1 MN, Bal, clade C: HIV-1 SE364) were preincubated with 1: 20, 1: 40 diluted sera or 1: 2.5, 1: 5 diluted fecal extracts from mice orally immunized with CVLPs (2-1, L1-MPER) or BPV VLPs. (D, E and F) 200pg of HIV-1 viruses (clade A: HIV-1 UG273, clade B: HIV-1 US4, clade D: HIV-1 UG274) were preincubated with 1: 20 diluted sera or 1: 2.5 diluted fecal extracts from mice orally immunized with CVLPs (2-1, L1-MPER) or BPV VLPs. The viruses was added to the CEM-NKR-CCR5 cells and virus replication was assessed by ELISA on day 9 by detecting p24 antigen in culture supernatants. Values are shown as mean ± S.D. (3-5 mice/group). * p < 0.05, ** p < 0.01. Data are representative of two independent experiments.